戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 dually decreased, while HS showed only minor decease.
2 or tropical cassava during sharp temperature decease.
3 splant and terminated when all patients were deceased.
4 am veterans who were alive in the 1980s were deceased.
5  observed SCr in a cohort of living (79) and deceased (67) donor allograft recipients followed up ove
6 n-years of follow-up, 263 study participants deceased, 89 due to CVD.
7 er factors impacting allograft survival from deceased AA kidney donors, APOL1 renal-risk variants wer
8  brain tissues of alcohol-dependent rats and deceased alcoholics, primarily in frontal and striatal a
9 gh-risk population occurred for 45.2% of the deceased and 40.4% of the survivors.
10 at compassionate and respectful care for the deceased and family, listening for and addressing family
11 he impact of the quality of the care for the deceased and for the family, (5) the content and manner
12 s to determine the effect of HLA matching on deceased and LD renal allograft outcomes in pediatric re
13  magnify and modify extant ethical issues in deceased and living donation related to privacy, confide
14 al, 0.32 to 1.01) ml/min per 1.73 m(2) among deceased and living donor kidney transplant recipients,
15 n addressing a diversity of issues including deceased and living organ donation, improving allograft
16 ucted, using variations of the search terms "deceased" and "controls" to identify relevant peer-revie
17            Empirical data from necropsies of deceased animals were then utilised to assess the conseq
18                              The eyes of the deceased babies were removed postmortem and were sent to
19 been explored that regulate the clearance of deceased cardiomyocytes by using the classic and reparat
20 s used deceased controls for comparison with deceased cases (n = 95; 70.9%).
21 cates their appropriateness in studies using deceased cases.
22                                              Deceased CFLD patients had lower platelet counts than th
23 ing child is older and less prominent if the deceased child was either disabled or an infant, suggest
24               Family 1 had one fetus and one deceased child with heterotaxy and complex congenital he
25 trated in postmortem ocular investigation of deceased children using immunohistochemical staining for
26 iew highlights the breadth of research using deceased controls and indicates their appropriateness in
27                 The majority of studies used deceased controls for comparison with deceased cases (n
28               Scholarly debate on the use of deceased controls in epidemiologic research continues.
29      The review identified 134 studies using deceased controls published in English between 1978 and
30  sought on study design, rationale for using deceased controls, application of theoretical principles
31 trol selection, and discussion of the use of deceased controls.
32 entation of DCD that enables an expansion of deceased donation (inclusive of DBD).
33 l and ethical issues pertaining to pediatric deceased donation and developed recommendations for poli
34 s the routine provision of opportunities for deceased donation by pediatric patients and conveys an i
35 to inform provision of best practice care in deceased donation for neonates and children.
36 g Unrelated Donor program and development of deceased donation in Iran.
37                Physicians who are focused on deceased donation medicine as part of their practice can
38                                              Deceased donation medicine involves unique ethical chall
39 ician role might promote ethical practice in deceased donation medicine.
40 tion Society convened a meeting on pediatric deceased donation of organs in Geneva, Switzerland, on M
41 s with voluntary, unpaid programs; associate deceased donation with being poor and marginal in societ
42                              Under Share 35, deceased donor (DD) livers are offered regionally to can
43 y anatomy), and (3) a patient simulated by a deceased donor (high-fidelity anatomy).
44    All patients received an allograft from a deceased donor (median donor age, 61.8 years).
45 m 2005 to 2009 after living donor (n=427) or deceased donor (n=548) renal transplant.
46 modeling showed divided-dose-rATG (P=0.019), deceased donor (P=0.003), serious infection (P=0.0.018),
47 waiting list or received a transplant from a deceased donor (waiting-list-or-transplant control group
48  and risk of GF was observed for HLA-DRB1 in deceased donor and living donor transplants.
49 d, in which ALA was administered both to the deceased donor and to the recipients; and (iii) recipien
50 rfusion biopsy associate with outcomes after deceased donor but not living donor renal transplants, t
51 rocortin-3(-) cells were seen in nondiabetic deceased donor control pancreatic islets.
52 gan Sharing database (2002-2011) queried for deceased donor first LT for primary biliary cirrhosis, p
53 ed the outcomes of 5,230 recipients of first deceased donor grafts transplanted during the period of
54 or even in need of, a kidney transplant, and deceased donor initiated chains in which chains are star
55 Replacement of pancreatic beta-cells through deceased donor islet transplantation is a proven therapy
56                                      The new deceased donor kidney allocation algorithm uses a Kidney
57             In December 2014, a new national deceased donor kidney allocation policy was implemented,
58 y Allocation System (KAS), a major change to deceased donor kidney allocation, was implemented in Dec
59 erstanding of factors that lead to increased deceased donor kidney discard can allow for targeted int
60 haracterized several important predictors of deceased donor kidney discard.
61  to better characterize the risk factors for deceased donor kidney discard.
62                The median waiting time for a deceased donor kidney in 2013 was 3.5 years.
63 ormed a retrospective cohort study of 47 563 deceased donor kidney match-runs from 2007 to 2013.
64                                   Optimizing deceased donor kidney quality opens new possibilities to
65 ted with the observed SCr in both living and deceased donor kidney recipients, correlation was strong
66 observed SCr was significantly greater among deceased donor kidney recipients, suggesting poorer func
67 zation, graft loss was substantially higher (deceased donor kidney transplant [DDKT] without delayed
68 gan Sharing data from 2003 to 2012 for adult deceased donor kidney transplant candidates was analyzed
69       Data from 61,927 adult recipients of a deceased donor kidney transplant in 1990 to 2012 registe
70  cells were measured by flow cytometry in 76 deceased donor kidney transplant recipients (DGF, n = 18
71 F and graft loss in pediatric and adolescent deceased donor kidney transplant recipients aged 21 year
72  an adult female patient who presented for a deceased donor kidney transplant with incidental finding
73 hospitalization rate and odds of receiving a deceased donor kidney transplant.
74 ealthier recipients and increasing access to deceased donor kidney transplantation (DDKT) for highly
75 nephropathy or ADPKD) than by lower rates of deceased donor kidney transplantation after waitlisting
76                         Induction therapy in deceased donor kidney transplantation is costly, with wi
77  within 3 years of transplantation in 19 450 deceased donor kidney transplantation recipients with Me
78 valuate HA effect on HO-1 upregulation after deceased donor kidney transplantation.
79 n donors and matched nondonors who underwent deceased donor kidney transplantation.
80                                It used 5% of deceased donor kidney transplanted in 2015.
81 isk of short- and long-term graft failure in deceased donor kidney transplants across the world.
82  for Organ Sharing data, we identified first deceased donor kidney transplants between October 1, 198
83                 Living and standard criteria deceased donor kidney transplants provide significant su
84  a retrospective cohort analysis of pairs of deceased donor kidney transplants where 1 kidney was all
85 ers, Shiraz undertakes the largest number of deceased donor kidney transplants, most liver transplant
86 es among recipients who received their first deceased donor kidney transplants.
87 tes who declined IRDs later received non-IRD deceased donor kidney transplants; the median KDPI of th
88 acellular histones in machine perfusates and deceased donor kidney viability.
89  the value of a living donor kidney versus a deceased donor kidney.
90         A significant proportion of procured deceased donor kidneys are subsequently discarded.
91 om 2003 to 2013, we identified recipients of deceased donor kidneys from the same donor in such a way
92 K Transplant Registry data were collected on deceased donor kidneys implanted between November 1, 201
93 , 66.3% of living donor kidneys and 50.7% of deceased donor kidneys received an optimal histology sco
94                            The proportion of deceased donor kidneys recovered for transplant but disc
95                        We identified 106,160 deceased donor kidneys recovered for transplant from 200
96 iopsy findings at the time of procurement of deceased donor kidneys remain the most common reason cit
97  of histologic classification, outcomes with deceased donor kidneys were inferior to outcomes with li
98                   Over the study period, 523 deceased donor kidneys were transplanted through the KFT
99                                              Deceased donor kidneys with AKI are often discarded for
100                            However, 73.2% of deceased donor kidneys with suboptimal histology remaine
101 r each involved party, the prioritization of deceased donor kidneys, the allocation of chain ending k
102   Pediatric kidneys constitute 10% to 12% of deceased donor kidneys.
103 ney transplants and increased utilization of deceased donor kidneys.
104 valent or beneficial alternative to awaiting deceased donor kidneys.
105  standard criteria, and 0% expanded criteria deceased donor KT (39%, 50%, and 11% in nondonors).
106 eceived a first-time live donor KT (LDKT) or deceased donor KT (DDKT) in 1990-2012.
107 nd Thymoglobulin appear equally effective in deceased donor KTRs maintained on tacrolimus/mycophenola
108                                  We examined deceased donor liver offer acceptance patterns and their
109 nd recipient characteristics associated with deceased donor liver organ offers for children who died
110 etherlands, DCDs were responsible for 30% of deceased donor liver transplant activity in 2015; Austri
111 ective review of 1300 patients who underwent deceased donor liver transplantation was performed.
112 shown that age is not a contraindication for deceased donor liver transplantation.
113 liary complications and graft survival after deceased donor liver transplantation.
114                                  Around 1600 deceased donor livers are transplanted annually.
115 d of patients aged >/=18 years who underwent deceased donor LT between January 1, 2003, and December
116                                    All adult deceased donor LTs from January 1, 2010, to March 31, 20
117 edures that included acceptance criteria for deceased donor organ pancreata and critical raw material
118 potentially inhibiting substantial growth in deceased donor organ transplants in Iran.
119 ft tolerance with a protocol compatible with deceased donor organ utilization.
120 gan donation, there is a chronic shortage of deceased donor organs.
121  the need for organ transplant and supply of deceased donor organs.
122 mentation, including the allocation of fewer deceased donor pediatric kidneys to children and stagnat
123 disease but its contribution to the national deceased donor pool is small.
124         Through comparison between the large deceased donor program in Shiraz and other centers in Ir
125 tween paid donation and the development of a deceased donor program.
126 0.04) more likely to experience MDR, as were deceased donor recipients (adjusted hazard ratio [aHR],
127                                          For deceased donor recipients, RDP was associated with signi
128 ved renal function (2-36 months; P<0.001) in deceased donor recipients.
129 of this study was to compare the outcomes of deceased donor renal allografts preserved with these flu
130                         The waiting time for deceased donor renal transplantation in the United State
131  theater that impact significantly on CIT in deceased donor renal transplantation, some of which are
132 raft function (DGF) in patients who received deceased donor renal transplants.
133                    In conclusion, this large deceased donor study shows enrichment of hypoxia and com
134                  Conversely, identifying the deceased donor tended to induce thoughts of death rather
135 o a 10-year-old child using a decellularized deceased donor trachea repopulated with the recipient's
136 nsplantation should be promoted by expanding deceased donor transplant programs and use of inexpensiv
137 morbidity score of 5 or greater, receiving a deceased donor transplant reduced the mortality risk by
138 posure level with death and graft loss after deceased donor transplantation were also observed.
139 n optimal and suboptimal kidneys only in the deceased donor transplants (P=0.02).
140 s a single-center retrospective study of all deceased donor transplants from 2004 to 2010 (n=359).
141 he expected survival benefits of living over deceased donor transplants were not present in membranop
142 aft survival was compared between living and deceased donor transplants within each glomerulonephriti
143  is not inferior to that of HLA well-matched deceased donor transplants.
144 and implementing the logistical workflow for deceased donor uterus procurement in a deceased multiorg
145                  We detail a new approach to deceased donor uterus procurement.
146 and our own initial experience, in which the deceased donor uterus was procured post cross-clamp and
147 tions regarding the most advantageous use of deceased donor versus living donor transplantation for p
148 rs was the primary outcome; placement on the deceased donor waiting list was also examined.
149 en during late adolescence, and differential deceased donor waiting times based on pediatric priority
150                  Even after placement on the deceased donor waitlist, there are racial disparities in
151 waiting list, whether or not a kidney from a deceased donor was received.
152  largest recovery of 11 organs from a single deceased donor with the transplantation of face, bilater
153 lls compared with high-fidelity simulations (deceased donor) (Nontechnical Skills video score: 95% CI
154                     We analyzed 1,679 adult, deceased donor, single-organ renal transplants occurring
155 s older than 65 years were transplanted with deceased donor, the mortality risk was reduced by 55% (h
156 rs for post-kidney transplantation SSIs were deceased donor, thin ureters at kidney transplantation,
157 splants-1021 with a living donor, 532 with a deceased donor-under our RDP protocol.
158 tation patients who receive the organ from a deceased donor.
159 dney transplants in the United States from a deceased donor.
160 res are readily accomplishable from the same deceased donor.
161 eous compared with waiting for a negative XM deceased donor.
162               Data were extracted for 12 902 deceased-donor kidney alone transplants performed in all
163 hether a patient will receive an offer for a deceased-donor kidney at Kidney Donor Profile Index thre
164                                       When a deceased-donor kidney is offered to a waitlisted candida
165            Multicenter, prospective study of deceased-donor kidney recipients to compare UNOS-DGF to
166 ant Recipients database who received a first deceased-donor kidney transplant (1995-2013).
167 le-center, observational study involving 319 deceased-donor kidney transplant recipients, we assessed
168  associated with worse allograft survival in deceased-donor kidney transplantation (DDKT) from AA don
169                                              Deceased-donor kidney transplantation is frequently perf
170  transplants is limited to a small number of deceased-donor kidney transplants from HIV-positive to H
171                                              Deceased-donor kidney transplants performed at the weeke
172 parable to those achieved nationally for all deceased-donor kidney transplants.
173                For patients waitlisted for a deceased-donor kidney, hospitalization is associated wit
174 d cohort analysis, obtaining data from every deceased-donor kidney-alone transplant procedure perform
175 ients were evaluated, 65% of whom received a deceased-donor kidney.
176 ero' biopsies for 371 consecutive, solitary, deceased-donor kidneys transplanted at our center betwee
177                                Assessment of deceased-donor organ quality is integral to transplant a
178                              The shortage of deceased-donor organs is compounded by donation metrics
179 larly sensitised patients cases listed for a deceased-donor transplant during that period.
180 ed associations between injury biomarkers in deceased-donor urine and the following outcomes: donor A
181  patients (panel reactive antibody > 80%), a deceased-donor-first strategy was advantageous, but for
182 ew listings (IRR, 1.02; P = 0.003), 100 more deceased donors (IRR, 1.23; P < 0.001), 100 more new dia
183                  Kidney transplantation from deceased donors aged 65 years or older is associated wit
184 ir application to the conduct of research on deceased donors and donor organs within the United State
185 atty acid binding protein (L-FABP) from 1304 deceased donors at organ procurement, among whom 112 (9%
186 ysis of the UK Transplant Registry evaluated deceased donors between 2003 and 2013.
187 EOB evaluated, constituting more than 30% of deceased donors coordinated annually by the NEOB.
188                                       Use of deceased donors for chain-initiating kidneys raises ethi
189 ective as using high-fidelity anatomies from deceased donors for promoting teamwork skills in this le
190 re conservatively 400 unrecognized potential deceased donors in Canada annually.
191  demonstrated a low prevalence of ZIKV among deceased donors in our community.
192 rative data can be used to identify possible deceased donors in the US and could be a data source for
193 act that kidney transplantation from elderly deceased donors is associated with reduced graft and pat
194 re and a concomitant increase on the rate of deceased donors per million population.
195 ated chains in which chains are started with deceased donors rather than altruistic living donors.
196 ation of organs from HIV-positive living and deceased donors to HIV-positive individuals with end-sta
197                       Fifty-six kidneys from deceased donors were recruited into the study.
198           The patients received kidneys from deceased donors who tested positive for HIV with the use
199 study was to evaluate the use of livers from deceased donors who were older than 75 years.
200 e than that of transplants from well-matched deceased donors with 0 to 1 HLA mismatch (log rank, P =
201 nsplantation, graft survival of kidneys from deceased donors with 0 to 1 HLA mismatches compares favo
202    The outcomes of recipients of organs from deceased donors with ITP recorded in the UK Transplant R
203           Organs from the 18- to 34-year-old deceased donors with PHS risks (but relatively few medic
204 00 kidneys (>17% of the total recovered from deceased donors) were discarded in 2013, despite evidenc
205 1 genotype differed from the genotype of the deceased donors, allowing us to differentiate liver- fro
206 of 80 or greater that were procured from 338 deceased donors.
207 on and those who waited for transplants from deceased donors.
208 s were compared with those from well-matched deceased donors.
209 s the rest of Iran's other centers were from deceased donors.
210 ients who received kidneys from HIV-positive deceased donors.
211  donation percentage (percentage of possible deceased-donors who become actual donors; range: 20.0-57
212 ly higher density in live versus prematurely deceased females indicating a potentially mutualistic as
213             Ocular tissue samples from the 4 deceased fetuses (2 female, 2 male) ranging from 21.5 to
214 April 30, 2017, ocular tissue samples from 4 deceased fetuses with a diagnosis of CZS from the Nation
215                   In a convenience sample of deceased football players who donated their brains for r
216 e neuropathological and clinical features of deceased football players with CTE.
217                                    Among 202 deceased former football players (median age at death, 6
218  Donors in the older group were mostly women deceased from stroke, and only 3 patients had experience
219 sequenced from lung samples originating from deceased giant pandas all possessed the substitutions V2
220 bserved using tools to clean the corpse of a deceased group member.
221                                          The deceased had fewer teeth and more oral infections.
222 andomized, open-label, monocenter trial, 160 deceased heart-beating donors were allowed to perform 23
223 val 0.39 - 0.72), effects that translated to deceased hospital length of stay [median hospital length
224 e interval [95% CI], 0.11-0.65) and standard deceased (HR, 0.52; 95% CI, 0.29-0.94) donor kidney tran
225    METHODS AND Small bowel was obtained from deceased humans, cows, and sheep supported with a contin
226 ta, we assessed patients with ovarian cancer deceased in 2000 to 2012 with at least 13 months of cont
227 8 to 395 months), 22 participants (13%) were deceased, including six deaths attributed to a meningiom
228              Three dimensional images of 157 deceased individuals (37 children, 120 skeletally mature
229 at preventing exposure from hospitalised and deceased individuals.
230                                          For deceased infants (n = 81), genetic disorders were molecu
231  evaluated in 127 normal adrenal glands from deceased kidney donors (age, 9 months to 68 years).
232  in 89 normal kidney samples from living and deceased kidney donors and normal poles of nephrectomies
233 omes in a prospective cohort study involving deceased kidney donors from five organ procurement organ
234 ied enteroadherent EPEC in the intestines of deceased kittens.
235 tion and hemorrhage in the adrenal glands of deceased mice.
236 d paraffin-embedded bone marrow samples from deceased MM patients were stained with LLP2A-Cy5.
237 w for deceased donor uterus procurement in a deceased multiorgan donor setting.
238  worsened (liver transplantation [LT] (n=5), deceased (n=2)).
239 on with DHA as observed in vivo, resulted in deceased Notch 1/Jagged 1 protein expression however, DH
240  implantation, 50.9% of patients were either deceased or in hospice.
241                                Outcomes were deceased or living donor transplant, death or removal fr
242  The influence of preference for type of KT (deceased or living donor) and transplant center location
243                  Grafts can be obtained from deceased or living donors, with different logistical req
244        Development of strategies to increase deceased organ donation is dependent on timely, accurate
245 idney donation offers superior outcomes over deceased organ donation, but incurs psychosocial and eth
246 from next of kin or family is sought for all deceased organ donation.
247 ere may be significant potential to increase deceased organ donations in Canada.
248 ntions on increasing the willingness to be a deceased organ donor (measured as commitment to donate a
249 m within the residual pancreatic islets of a deceased organ donor who had T1D.
250              Compared with the standard risk deceased organ donor, the PHS donor was younger, male, d
251 rease the willingness of individuals to be a deceased organ donor.
252  intracranial hemorrhage than were all other deceased organ donors (85% vs. 57%, p < 0.001).
253    Our primary outcome measure was potential deceased organ donors (identified by the presence of dia
254                                              Deceased organ donors are routinely screened for behavio
255                         Current screening of deceased organ donors by RPR yields a significant number
256 urrent U.S. policy requires screening of all deceased organ donors for syphilis infection.
257                         We identified all UK deceased organ donors from 2003 to 2015 with a disclosed
258                                   Twenty-one deceased organ donors had a predonation diagnosis of ITP
259 tive was to estimate the number of potential deceased organ donors in Canada.
260 le for 75% of the increase in the numbers of deceased organ donors in the United Kingdom.
261 After the 2013 modification, over 20% of all deceased organ donors in the United States were identifi
262                                The number of deceased organ donors remains stable but donor age is in
263         Thirty-two of 3,555 (0.9%) potential deceased organ donors screened during the study period s
264                 Positive ZIKV tests in local deceased organ donors were investigated from 6/2016 to 1
265 sequencing (RNA-seq) on islets from multiple deceased organ donors, including children, healthy adult
266 nformation regarding the number of potential deceased organ donors.
267 ath (DCD) provides an alternative pathway to deceased organ transplantation.
268 om 2009-2012, 96,028 (3.3%) were a "possible deceased-organ donor." The two proposed metrics of OPO p
269  over a 24-year period (1988-2012) for 3,238 deceased participants (43.9% men).
270 e study included 286 autopsied brains of 554 deceased participants (51.6%).
271                  Cross-sectional analyses of deceased participants in the Memory and Aging Project cl
272 etic, and transcriptional data available for deceased participants of the Religious Orders Study (n =
273 5), parent (3), or other relation (1) of the deceased patient.
274 aseline efflux capacity was not different in deceased patients and survivors (P=0.60 or P=0.50 for ca
275                                              Deceased patients had fewer teeth (P <0.001) and higher
276                 Median time to death for 131 deceased patients was 14 mo; median follow-up of living
277 s, globus pallidus, and thalamus of these 23 deceased patients were harvested and analyzed with induc
278                                The charts of deceased patients were reviewed for liver biopsy to eval
279     Methods We interviewed 2,307 families of deceased patients with advanced lung or colorectal cance
280                                      Of 1490 deceased patients, 620 (41.6%) died of ocular melanoma.
281 mily overrule of donation of solid organs by deceased patients, and examine arguments both in favor o
282 amilies to receive money for donation from a deceased person, who is at no risk of harm, will make it
283 mined published epidemiologic research using deceased persons as a control group.
284                       Participants were 1096 deceased persons from two clinical-pathologic studies.
285 l origin of 83% of alleles, and genotypes of deceased recent ancestors for whom no genotype informati
286 who give permission for the removal of their deceased relative's organs for transplantation exist in
287 en asked to consent to the donation of their deceased relative's organs or tissues.
288  donation themselves, donate the organs of a deceased relative, or support a transition to an "opt-ou
289 ion commitment cards, donate the organs of a deceased relative, support the transition to an "opt-out
290    We used a database comprising 1.4 million deceased soldiers to identify war orphans and collect in
291 ars) is worse than younger LD but similar to deceased standard criteria donors (SCD).
292 donors and living donors, as alternatives to deceased standard criteria donors.
293  and pathological data were derived from 607 deceased subjects (mean age at death, 89 years; 66% wome
294        GLS and EF were both more abnormal in deceased than in those alive by day-28 follow-up (both P
295 nd (6) the characteristics of the family and deceased that affect the request for family consent.
296 25 hemodialysis patients who underwent first deceased transplantion.
297 erall survival benefit was 62% versus 70% in deceased versus living donor transplanted patients.
298 FLD (143 versus 258 U/L, P = 0.004) or those deceased with no CFLD (143 versus 327U/L, P = 0.006).
299 ncluded 4256 patients with ALS (3125 [73.4%] deceased) with genotype data extended to 7174392 variant
300 low-up of 49 months), 71.6% of patients were deceased, with median survival time of 11 months for tho

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top